File: '\\swfile\EmailIn\20260202 161754 Attachment Noveris - news release announcing Chief Strategy Officer - February 2026.docx'

LEGAL_48771253.1

NOVERIS ANNOUNCES CHIEF STRATEGY OFFICER

Vancouver, BC - February 2, 2026: Noveris Health Sciences Inc. (the "Company") (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce the appointment of Jason Birmingham as Chief Strategy Officer of the Company effective immediately.

Mr. Birmingham has over 33 years of experience as an entrepreneurial executive and consulting professional. Mr. Birmingham brings to the Company hands-on experience in domestic and international private and public company start-ups.

Since April 1999 he has run his own consulting business and has been involved with many companies in the capacities of founder/principal, senior officer, director and/or financier. He brings experience with project generation, deal negotiation & acquisition, corporate structuring & strategic planning, private and public company fiance & regulatory compliance, public & investor relations marketing and board & committee activities. Industries served include resource exploration/exploitation, technology, hospitality and agri-business. He has been a director of several publicly listed companies on the TSX Venture Exchange and Canadian Securities Exchange. His network of contacts within the financial and business community extends across North America and Europe.

Jason completed the Canadian Securities Course in 1995 and completed the Real Estate Salesperson's Sub-Mortgage Broker's Pre-Licensing Course through the Faculty of Commerce and Business Administration, at the University of British Columbia in 1996.

About Noveris Health Sciences Inc.

Noveris Health Sciences Inc.(TM) is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Noveris' dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world's leading specialists, the Company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Noveris' approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with worldclass scientific and regulatory expertise.

Learn more at: https://www.noveris.com/ and follow the company on Twitter, LinkedIn, YouTube, and Instagram.

On behalf of the Board of Directors,

NOVERIS HEALTH SCIENCES INC.

Joshua Bartch

Chief Executive Officer

Email: contact@mydecineinc.com

Phone: +1 (888) 871 - 3936

The Canadian Securities Exchange has not in any way passed upon the merits of the matters referenced herein and has neither approved nor disapproved the contents of this news release.